Sanofi Announces Participation in 2nd China International Import Expo
SHANGHAI, July 26, 2019 /PRNewswire/ -- At today's Matchmaking Meeting for Medical Devices and Medical Health Care Exhibitors and Buyers of the 2nd China International Import Expo (CIIE), Sanofi officially announced that it would participate in the 2nd CIIE held in the National Convention and Exhibition Center (Shanghai) from November 5 to 10.
As a world leading healthcare company, Sanofi will participate in this event as a second time. At the first CIIE, Sanofi demonstrated the excellent global R&D achievements, the process of cooperation with partners throughout the industry, the long-term commitment to the health needs of the Chinese people to China and the world, and also expressed Sanofi's positive role in China's healthy ecosystem.
This year, Sanofi expanded the exhibition area in the Medical Equipment & Health Care Products Exhibition Area of CIIE. Sanofi will demonstrate its breakthrough pipeline drugs and vaccines that will be actively introduced in China in the near future, as well as the digital innovative medical solutions to meet the diversified health needs, based on understanding of the health needs of the Chinese people.
"As a trusted healthcare partner in China for 37 years, Sanofi is very honored to participate in the CIIE again, especially during the 70th anniversary of the founding of the People's Republic of China," said Pius S. Hornstein PhD, Country Chair of Sanofi China. "CIIE is a significant platform to showcase advanced science & technology across the world. Sanofi will continue to be an active participant and innovation advocate - we will introduce over 20 new medicines and vaccines by 2025, strive to become the best digital healthcare company, and ultimately improve health for the broadest base of the Chinese people."
As one of the first multinational healthcare companies entering into China, Sanofi grew with the development of Chinese pharmaceutical health industry. Over 9,000 Sanofi employees have served millions of patients in over 2,000 cities and counties, by providing innovative and universal health coverage: we stepped into counties and have covered 760 million county people. Every year, our vaccines have provided immunization and disease prevention for over 12 million people in China. Our innovative prescription medicines benefit patients nearly 10 million with diabetes and cardiovascular disease, more than 60,000 with cancer and over 600 with rare disease. Dedicated to empowering the lives of the 1.4 billion people in China, our R&D and industrial footprints have been expanding: Sanofi established Global R&D Operations Hub in Chengdu, and China Research Institute in Suzhou (announced and to be launched).
The CIIE, hosted by the Ministry of Commerce of the People's Republic of China and the Shanghai Municipal People's Government, is the first state-level exposition focusing on imports. The cumulative turnover of the first CIIE is 57.83 billion US dollars. According to the data released today at the Countdown 100-day Press Conference of the 2nd CIIE, 61 national exhibitors and more than 3,000 companies from more than 150 countries and regions have confirmed their participation in this expo.
About Sanofi, China
In 1982, Sanofi opened its first office in China. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. Sanofi's China headquarters in Shanghai are supported by 11 offices in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi. Sanofi has more than 9,000 employees in China.
Sanofi has three manufacturing facilities in China to meet the increasing demand of the domestic market. These plants are located in Beijing, Hangzhou and Shenzhen.
Sanofi established Global R&D Operations Hub in Chengdu, and China Research Institute in Suzhou (announced and to be launched). Sanofi's R&D focuses on unmet medical needs, such as oncology, immunology, and metabolic diseases in China and the rest of the world.
For more information, please visit www.sanofi.cn or subscribe to the Sanofi China official WeChat account: SanofiChina and LinkedIn account: Sanofi.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2018. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.